



Weston Family Foundation

Microbiome Committee MINT – Letter of Intent

DEADLINE: October 30, 2026, 2:00pm ET

Applicants will be notified of Proposal invitations in November 2026.

This Letter of Intent (LOI) is an example only. Do not complete this paper application.
Please submit the Letter of Intent online through the Foundation's grant management system. Please visit our website for more details at [our program webpage](#).

Please review the [Program Details document](#) prior to submission as it provides specifics on the information we require.

Short Summary: Microbiome Innovations for New Therapies (MINT) supports translational microbiome research that advances interventions toward clinical and commercial application. The program focuses on de-risking promising discoveries and building a pipeline of scalable interventions with the potential for real-world impact to decrease or improve chronic disease health outcomes for Canadians. The program also includes an integrated mentorship component, providing grantees with guidance from industry experts to support the commercialization and development of their interventions.

Projects that demonstrate strong progress in Stage I will have the opportunity to apply for additional funding in Stage II of up to \$2,000,000 to further advance and scale their interventions. Projects that are positioned to conduct clinical trials in the second stage of the granting program (at \$2,000,000) will be prioritized.

Project Title:

Applicant Details:

Team Members	Organizations	Primary Contact Information	Role in Project	Estimated Time Spent on Project
1. Salutation:	Primary Organization:	Address:	☐ Principal Applicant	%
First Name:	Position Title:	Phone:	☐ Co-Applicant	
Last Name:	Other Affiliations/ Position Titles:	Email:	☐ Collaborator	



Weston Family Foundation
Fondation de la famille Weston

2. Salutation:	Primary Organization:	Address:	☐ Principal Applicant	%
First Name:	Position Title:	Phone:	☐ Co-Applicant	
Last Name:	Other Affiliations/ Position Title:	Email:	☐ Collaborator	

*Note: Participants are not limited to two team members/organizations as laid out; LOI may include as many team members/organizations as needed for the successful execution of the project, though there must be only a **single principal applicant identified**. Please refer to Program Details document for more information.*

Project Details

1. Describe how the lead applicant or organization is qualified to undertake a project of this scale and expand upon your capacity and experience to deliver this project successfully. *Max 200 words*
2. Outline the key objectives of the project and how they directly address the program goals and desired impact described in the Program Details. What innovations are proposed? *Max 350 words*
3. Justify the disease or health condition that is the focus of this project. Define the scope and burden of the disease, explain its relevance and importance to Canadians, and describe why this indication is an important priority for a microbiome-based intervention within the goals of this program. *Max 250 words*
4. Succinctly describe the main activities planned for the implementation of the proposed project, including an estimated timeline and identification of areas presenting the greatest uncertainty or risk. Include reference to any prior pilots, peer-reviewed work or established sector/industry best practices that are being incorporated or leveraged throughout project execution. *Max 500 words*
5. Describe how this project can be scaled in the future to positively affect more than the scope currently defined by this project? *Max 250 words*
6. The Weston Family Foundation is requiring an [Integrated Development Plan \(IDP\)](#) as part of the grant application process. The IDP should align with the project's proposed translational pathway and outline steps required to advance toward clinical and/or commercial implementation. Applicants should use the IDP as an opportunity to describe the knowledge mobilization and implementation process for the discoveries of their project. This will include aspects of stakeholder engagement, clinical and regulatory development, and manufacturing strategy,



Weston Family Foundation
Fondation de la famille Weston

where applicable. Please upload a completed IDP relevant to your project. The IDP is used in the evaluation process, so be sure to tailor the template IDPs to the specific needs of your project. Applicants may use AI tools/models to support landscape review and help inform strategic thinking in the IDP. However, applicants should not enter confidential, proprietary, unpublished, or personally identifiable information into external AI tools. Applicants remain responsible for the accuracy, judgment, and appropriateness of all content submitted. You are encouraged to contact microbiome@westonfoundation.ca with any questions.

Budget

7. What is the total estimated cost for this project? Of this, how much is expected to be requested from the Weston Family Foundation?

While there is no need for a detailed budget, please provide a list of major expense categories, indicating where the bulk of funding will be spent. Major expense categories may include personnel, equipment/lab supplies, field study costs, education and knowledge mobilization, consultant fees (e.g., IP, regulatory, or business strategy services), communications and marketing.



Weston Family Foundation
Fondation de la famille Weston

1. Which disease area best aligns with the project?

(drop down list)

- Gastrointestinal Diseases (e.g. irritable bowel syndrome, inflammatory bowel disease)
- Obesity, Diabetes and Metabolic Diseases
- Neurological Diseases (e.g. Parkinson's disease, Alzheimer's disease)
- Neurodevelopmental Conditions
- Anxiety, Depression and other Mood Disorders
- Immunology, Autoimmunity and Allergic Diseases
- Cancer
- Cardiovascular Diseases
- Other *Please specify:*

2. If applicable, please indicate the type(s) of research that is conducted in this project

- Human observational research
- Pre-clinical research
- IND-enabling studies
- Phase 0/1 clinical research
- Phase 2 clinical research
- Other *Please specify:*

3. Preliminary data: A maximum of 1 page of preliminary data (non-narrative) that best supports the application is required and can be uploaded as a PDF file, e.g., figures or tables.

4. List of publications cited in the application: Please include full citations and PMID. *Maximum 600 words*

The review panel for this program is predominantly comprised of international reviewers based outside of Canada. Please list the full names (first and last names) of any individuals located outside of Canada who are competitive with your research and therefore should not review your application. Please do not exclude individuals for other reasons as we are unable to honour those requests. Type "None" if you have no reviewer exclusion. (This information will not be used to assess the application.)
